AstraZeneca's BREZTRI wins US approval for asthma treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AstraZeneca Q1 preview: In-line quarter expected as pipeline catalysts take center stage
April 28, 2026 4:00 PM EDTAstraZeneca (NASDAQ: AZN) reports first-quarter results on Wednesday, with analysts expecting a solid but unexciting print, as investor focus shifts firmly toward a busy second-half pipeline newsflow that Bank of America says could drive a meaningful re-rating of the stock.
BofA analyst Sachin Jain said in a preview note released at the start of April... More
